{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T17:59:43Z","timestamp":1794679183754,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41591-026-04244-6","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:03:09Z","timestamp":1774432989000},"page":"1257-1266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study"],"prefix":"10.1038","volume":"32","author":[{"given":"Ning","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1567-7458","authenticated-orcid":false,"given":"Peiling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Parone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-7133","authenticated-orcid":false,"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"4244_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Primers 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"4244_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar, S. K. et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26, 149\u2013157 (2012).","journal-title":"Leukemia"},{"key":"4244_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4244_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu, B., Jiang, T. & Liu, D. BCMA-targeted immunotherapy for multiple myeloma. J. Hematol. Oncol. 13, 125 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"4244_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4244_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"4244_CR7","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood 137, 2890\u20132901 (2021).","journal-title":"Blood"},{"key":"4244_CR8","doi-asserted-by":"crossref","unstructured":"Chen, W. et al. Phase II study of fully human BCMA-targeting CAR-T cells (zevorcabtagene autoleucel) in patients with relapsed\/refractory multiple myeloma. Exp. Hematol. Oncol.14, 119 (2025).","DOI":"10.1186\/s40164-025-00710-y"},{"key":"4244_CR9","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","volume":"9","author":"FL Locke","year":"2025","unstructured":"Locke, F. L. et al. Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel. Blood Adv. 9, 2663\u20132676 (2025).","journal-title":"Blood Adv."},{"key":"4244_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini, L. et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat. Rev. Clin. Oncol. 19, 342\u2013355 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4244_CR11","doi-asserted-by":"crossref","unstructured":"Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C. & Chen, Y. Y. CAR-T cell manufacturing: major process parameters and next-generation strategies. J. Exp. Med. 221, e20230903 (2024).","DOI":"10.1084\/jem.20230903"},{"key":"4244_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody, S. et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat. Med. 29, 422\u2013429 (2023).","journal-title":"Nat. Med."},{"key":"4244_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"4244_CR14","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","volume":"29","author":"A Heczey","year":"2023","unstructured":"Heczey, A. et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat. Med. 29, 1379\u20131388 (2023).","journal-title":"Nat. Med."},{"key":"4244_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","volume":"22","author":"C Diorio","year":"2025","unstructured":"Diorio, C., Teachey, D. T. & Grupp, S. A. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks. Nat. Rev. Clin. Oncol. 22, 10\u201327 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4244_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"4244_CR17","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311\u20131317 (2025).","journal-title":"Science"},{"key":"4244_CR18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai, C. J. et al. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood 144, 977\u2013987 (2024).","journal-title":"Blood"},{"key":"4244_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00508-1","volume":"11","author":"W Nawaz","year":"2021","unstructured":"Nawaz, W. et al. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J. 11, 119 (2021).","journal-title":"Blood Cancer J."},{"key":"4244_CR20","doi-asserted-by":"crossref","unstructured":"Bozza, M. et al. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Sci. Adv. 7, eabf1333 (2021).","DOI":"10.1126\/sciadv.abf1333"},{"key":"4244_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"4244_CR22","doi-asserted-by":"crossref","unstructured":"Xu, J. et al. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet 406, 228\u2212231 (2025).","DOI":"10.1016\/S0140-6736(25)01030-X"},{"key":"4244_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2020","unstructured":"Yakoub-Agha, I. et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105, 297\u2013316 (2020).","journal-title":"Haematologica"},{"key":"4244_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.20892\/j.issn.2095-3941.2022.0612","volume":"20","author":"H Fan","year":"2023","unstructured":"Fan, H. et al. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study. Cancer Biol. Med. 20, 77\u201387 (2023).","journal-title":"Cancer Biol. Med."},{"key":"4244_CR25","doi-asserted-by":"publisher","first-page":"979111","DOI":"10.3389\/fphar.2023.979111","volume":"14","author":"W Tang","year":"2023","unstructured":"Tang, W. et al. Treatment attrition rates and relevant risk factors in multiple myeloma: a real-world study in China. Front. Pharmacol. 14, 979111 (2023).","journal-title":"Front. Pharmacol."},{"key":"4244_CR26","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.bbmt.2020.08.018","volume":"26","author":"AJ Cowan","year":"2020","unstructured":"Cowan, A. J. et al. The global state of hematopoietic cell transplantation for multiple myeloma: an analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. Biol. Blood Marrow Transplant. 26, 2372\u20132377 (2020).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"4244_CR27","doi-asserted-by":"crossref","unstructured":"Milani, M. et al. Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. Sci. Transl. Med. 11, eaav7325 (2019).","DOI":"10.1126\/scitranslmed.aav7325"},{"key":"4244_CR28","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.15252\/emmm.201708148","volume":"9","author":"M Milani","year":"2017","unstructured":"Milani, M. et al. Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy. EMBO Mol. Med. 9, 1558\u20131573 (2017).","journal-title":"EMBO Mol. Med."},{"key":"4244_CR29","doi-asserted-by":"crossref","unstructured":"Wang, Y. & Shao, W. Innate immune response to viral vectors in gene therapy. Viruses 15, 1801 (2023).","DOI":"10.3390\/v15091801"},{"key":"4244_CR30","doi-asserted-by":"crossref","unstructured":"Kim, J. T. et al. Dendritic cell\u2212targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation. Sci. Immunol. 2, eaal1329 (2017).","DOI":"10.1126\/sciimmunol.aal1329"},{"key":"4244_CR31","doi-asserted-by":"publisher","first-page":"1213270","DOI":"10.3389\/fmicb.2023.1213270","volume":"14","author":"SS Ganaie","year":"2023","unstructured":"Ganaie, S. S., Wang, Z., Su, B. & Mir, S. Editorial: Virus-induced innate immune response and inflammation. Front. Microbiol. 14, 1213270 (2023).","journal-title":"Front. Microbiol."},{"key":"4244_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/imt-2020-0188","volume":"13","author":"J Huang","year":"2021","unstructured":"Huang, J., Rong, L., Wang, E. & Fang, Y. Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy. Immunotherapy 13, 5\u201310 (2021).","journal-title":"Immunotherapy"},{"key":"4244_CR33","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41409-020-01156-y","volume":"56","author":"I Danylesko","year":"2021","unstructured":"Danylesko, I. et al. Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplant. 56, 1134\u20131143 (2021).","journal-title":"Bone Marrow Transplant."},{"key":"4244_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36\u201349 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"4244_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao, X. et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J. Exp. Clin. Cancer Res. 40, 367 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"4244_CR36","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1182\/blood-2024-206559","volume":"144","author":"J Butman","year":"2024","unstructured":"Butman, J. et al. Steroid prophylaxis in patients receiving CAR T-cell therapy for relapsed and refractory non-Hodgkin lymphoma. Blood 144, 4507\u20134507 (2024).","journal-title":"Blood"},{"key":"4244_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01048-0","volume":"14","author":"BA Costa","year":"2024","unstructured":"Costa, B. A. et al. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 14, 84 (2024).","journal-title":"Blood Cancer J."},{"key":"4244_CR38","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","volume":"10","author":"C Li","year":"2024","unstructured":"Li, C. et al. Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial. JAMA Oncol. 10, 1681\u20131688 (2024).","journal-title":"JAMA Oncol."},{"key":"4244_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0337-y","volume":"10","author":"A Dogan","year":"2020","unstructured":"Dogan, A. et al. B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer J. 10, 73 (2020).","journal-title":"Blood Cancer J."},{"key":"4244_CR40","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1016\/j.healun.2019.01.617","volume":"38","author":"I Kim","year":"2019","unstructured":"Kim, I., Wu, G., Chai, N., Jordan, S. & Klein, A. Dynamic BCMA expression by alloreactive B cells coupled with donor specific antibody production during de novo alloantibody responses. J. Heart Lung Transplant. 38, S249 (2019).","journal-title":"J. Heart Lung Transplant."},{"key":"4244_CR41","doi-asserted-by":"publisher","first-page":"10845","DOI":"10.3390\/ijms251910845","volume":"25","author":"J Martin","year":"2024","unstructured":"Martin, J. et al. B-cell maturation antigen (BCMA) as a biomarker and potential treatment target in systemic lupus erythematosus. Int. J. Mol. Sci. 25, 10845 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"4244_CR42","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1182\/blood-2008-12-192559","volume":"113","author":"K Maeda","year":"2009","unstructured":"Maeda, K. et al. Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals. Blood 113, 4534\u20134540 (2009).","journal-title":"Blood"},{"key":"4244_CR43","doi-asserted-by":"publisher","first-page":"1437864","DOI":"10.3389\/fimmu.2024.1437864","volume":"15","author":"Y Sun","year":"2024","unstructured":"Sun, Y. et al. Early B lymphocyte subsets in blood predict prognosis in sepsis. Front. Immunol. 15, 1437864 (2024).","journal-title":"Front. Immunol."},{"key":"4244_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41421-021-00296-9","volume":"7","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Dysregulated hematopoiesis in bone marrow marks severe COVID-19. Cell Discov. 7, 60 (2021).","journal-title":"Cell Discov."},{"key":"4244_CR45","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4244_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2020-134378","volume":"136","author":"N Martin","year":"2020","unstructured":"Martin, N. et al. Idecabtagene vicleucel (ide-cel, bb2121) responses are characterized by early and temporally consistent activation and expansion of CAR T cells with a T effector phenotype. Blood 136, 17\u201318 (2020).","journal-title":"Blood"},{"key":"4244_CR47","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.ymthe.2020.07.006","volume":"28","author":"JF Wright","year":"2020","unstructured":"Wright, J. F. Quantification of CpG motifs in rAAV genomes: avoiding the Toll. Mol. Ther. 28, 1756\u20131758 (2020).","journal-title":"Mol. Ther."},{"key":"4244_CR48","doi-asserted-by":"publisher","first-page":"1371596","DOI":"10.3389\/fbioe.2024.1371596","volume":"12","author":"AI Paremskaia","year":"2024","unstructured":"Paremskaia, A. I. et al. Codon-optimization in gene therapy: promises, prospects and challenges. Front. Bioeng. Biotechnol. 12, 1371596 (2024).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"4244_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61666-3","volume":"14","author":"T Yoshida","year":"2024","unstructured":"Yoshida, T. et al. Introduction of sugar-modified nucleotides into CpG-containing antisense oligonucleotides inhibits TLR9 activation. Sci. Rep. 14, 11540 (2024).","journal-title":"Sci. Rep."},{"key":"4244_CR50","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"4244_CR51","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04244-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04244-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04244-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:02:57Z","timestamp":1776780177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04244-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4244"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04244-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.P. is employed by and owns stocks in EsoBiotec. J.Z. is employed by and owns stocks in Shenzhen Pregene Biopharma Company. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}